{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:17:39Z","timestamp":1793247459485,"version":"4.5.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.drup.2024.101053","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T11:48:53Z","timestamp":1706269733000},"page":"101053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges"],"prefix":"10.1016","volume":"73","author":[{"given":"Shaoqing","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2024.101053_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00363-17","article-title":"Antiviral activity and resistance analysis of NS3\/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in hepatitis C virus GT4 replicons","volume":"61","author":"Asante-Appiah","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2024.101053_bib2","doi-asserted-by":"crossref","first-page":"11420","DOI":"10.1021\/acs.jmedchem.0c00242","article-title":"Fragment linking strategies for structure-based drug design","volume":"63","author":"Bancet","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib3","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1021\/jm301271j","article-title":"Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening","volume":"56","author":"Bauman","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101004","article-title":"Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer","volume":"71","author":"Bharathiraja","year":"2023","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.drup.2024.101053_bib5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/14712598.2.7.751","article-title":"HIV-1 drug resistance: can we overcome?","volume":"2","author":"Brenner","year":"2002","journal-title":"Expert Opin. Biol. Th"},{"key":"10.1016\/j.drup.2024.101053_bib6","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"biochemistry"},{"key":"10.1016\/j.drup.2024.101053_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an RTK case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib8","doi-asserted-by":"crossref","first-page":"9725","DOI":"10.1073\/pnas.1711463114","article-title":"Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography","volume":"114","author":"Chan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2024.101053_bib9","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.4155\/tde.12.99","article-title":"Multivalent ligand: design principle for targeted therapeutic delivery approach","volume":"3","author":"Chittasupho","year":"2012","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.drup.2024.101053_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jmb.2006.07.073","article-title":"Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring","volume":"363","author":"Cihlar","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib11","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","article-title":"Avoiding drug resistance in HIV reverse transcriptase","volume":"121","author":"Cilento","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drup.2024.101053_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV Population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"Coffin","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.drup.2024.101053_bib13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/nature06956","article-title":"Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants","volume":"453","author":"Collins","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.drup.2024.101053_bib14","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1021\/jm201376w","article-title":"Discovery of 1,2,4-triazine derivatives as adenosine A2A antagonists using structure based drug design","volume":"55","author":"Congreve","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib15","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3390\/molecules25061338","article-title":"2-(Arylamino)-6-(trifluoromethyl)nicotinic acid derivatives: new HIV-1 RT dual inhibitors active on viral replication","volume":"25","author":"Corona","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drup.2024.101053_bib16","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1021\/jacs.8b01233","article-title":"Small molecule targeted recruitment of a nuclease to RNA","volume":"140","author":"Costales","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drup.2024.101053_bib17","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.chembiol.2019.04.008","article-title":"Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA","volume":"26","author":"Costales","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib18","doi-asserted-by":"crossref","first-page":"8402","DOI":"10.1021\/acs.jmedchem.8b00931","article-title":"Structure-based drug design of potent pyrazole derivatives against rhinovirus replication","volume":"61","author":"Da Costa","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted protein degradation: from chemical biology to drug discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41589-019-0225-6","article-title":"Designing a chemical inhibitor for the AAA protein spastin using active site mutations","volume":"15","author":"Cupido","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib21","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1073\/pnas.0711209105","article-title":"High-resolution structures of HIV-1 reverse transcriptase\/TMC278 complexes: Strategic flexibility explains potency against resistance mutations","volume":"105","author":"Das","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2024.101053_bib22","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/jm030558s","volume":"47","author":"Das","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pbiomolbio.2004.07.001","article-title":"Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"88","author":"Das","year":"2005","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2024.101053_bib25","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/jac\/dkt249","article-title":"Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence","volume":"68","author":"Delobel","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2024.101053_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of \u03b2-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.drup.2024.101053_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00003495-199958040-00016","article-title":"Zanamivir: a review of its use in influenza","volume":"58","author":"Dunn","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2024.101053_bib28","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4155\/fmc.14.50","article-title":"Conformational restriction: an effective tactic in \u2019follow-on\u2019-based drug discovery","volume":"6","author":"Fang","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib29","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/0008-5472.CAN-07-0345","article-title":"Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target","volume":"67","author":"Fern\u00e1ndez","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.drup.2024.101053_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/138161282005140214161949","article-title":"Structure-based drug design to overcome drug resistance: challenges and opportunities","volume":"20","author":"Ferreira","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.drup.2024.101053_bib31","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1021\/jm100488w","article-title":"Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors","volume":"53","author":"Ferreira","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100991","article-title":"Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment","volume":"71","author":"Focosi","year":"2023","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.drup.2024.101053_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.me.42.020191.001335","article-title":"Resistance of viruses to antiviral drugs","volume":"42","author":"Freifeld","year":"1991","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.drup.2024.101053_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nbt0102-15","article-title":"Designing drugs against heterogeneous targets","volume":"20","author":"Freire","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.drup.2024.101053_bib35","doi-asserted-by":"crossref","first-page":"19501","DOI":"10.1021\/ja3092642","article-title":"Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design","volume":"134","author":"Frey","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drup.2024.101053_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1743-422X-6-67","article-title":"Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis","volume":"6","author":"Furuse","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.drup.2024.101053_bib37","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1128\/AAC.00650-09","article-title":"Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance","volume":"53","author":"Furuse","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2024.101053_bib38","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1021\/acs.jmedchem.6b00537","article-title":"Structure-based tetravalent zanamivir with potent inhibitory activity against drug-resistant influenza viruses","volume":"59","author":"Fu","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.apsb.2021.08.027","article-title":"Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors","volume":"12","author":"Gao","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2024.101053_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115927","article-title":"Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C","volume":"30","author":"Gao","year":"2021","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100934","article-title":"Mapping cryptic binding sites of drug targets to overcome drug resistance","volume":"67","author":"Gao","year":"2023","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.drup.2024.101053_bib42","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/anie.201102762","article-title":"Enhancing protein backbone binding-a fruitful concept for combating drug-resistant HIV","volume":"51","author":"Ghosh","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.drup.2024.101053_bib43","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000350417","article-title":"Use of allosteric targets in the discovery of safer drugs","volume":"22","author":"Grover","year":"2013","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.drup.2024.101053_bib44","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1021\/jm040838n","article-title":"Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1","volume":"48","author":"Guillemont","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib45","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1021\/jp312396q","article-title":"Structural comparison of the wild-type and drug-resistant mutants of the influenza A M2 proton channel by molecular dynamics simulations","volume":"117","author":"Gu","year":"2013","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.drup.2024.101053_bib46","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/acscentsci.0c00984","article-title":"Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders","volume":"6","author":"Haniff","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.drup.2024.101053_bib47","article-title":"Plasticity of 150-loop in influenza neuraminidase explored by hamiltonian replica exchange molecular dynamics simulations","volume":"8","author":"Han","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drup.2024.101053_bib48","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1021\/jp807442n","article-title":"Understanding the mechanism of drug resistance due to a codon deletion in protoporphyrinogen oxidase through computational modeling","volume":"113","author":"Hao","year":"2009","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.drup.2024.101053_bib49","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17460441.2019.1626821","article-title":"Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors","volume":"14","author":"Hao","year":"2019","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.drup.2024.101053_bib50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1124\/mol.111.073189","article-title":"Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S\/GSK1349572)","volume":"80","author":"Hare","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.drup.2024.101053_bib51","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1021\/acschembio.9b00370","article-title":"Picomolar to micromolar: elucidating the role of distal mutations in HIV-1 protease in conferring drug resistance","volume":"14","author":"Henes","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib52","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"H\u00e9zode","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2024.101053_bib53","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1021\/acs.jmedchem.7b01709","article-title":"Identification of highly potent human immunodeficiency virus type-1 protease inhibitors against lopinavir and darunavir resistant viruses from allophenylnorstatine-based peptidomimetics with P2 tetrahydrofuranylglycine","volume":"61","author":"Hidaka","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2055-6640(20)30871-2","article-title":"How can we achieve universal access to low-cost treatment for HIV?","volume":"2","author":"Hill","year":"2016","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.drup.2024.101053_bib55","doi-asserted-by":"crossref","first-page":"11074","DOI":"10.1021\/acs.jmedchem.8b01098","article-title":"Identification of selective dual ROCK1 and ROCK2 inhibitors using structure-based drug design","volume":"61","author":"Hobson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib56","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/pro.2158","article-title":"Structural basis for proton conduction and inhibition by the influenza M2 protein: Structure and function of the TM domain of M2","volume":"21","author":"Hong","year":"2012","journal-title":"Protein Sci."},{"key":"10.1016\/j.drup.2024.101053_bib57","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.apsb.2021.11.018","article-title":"Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins","volume":"12","author":"Hou","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2024.101053_bib58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.drup.2024.101053_bib59","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib60","doi-asserted-by":"crossref","first-page":"2000556","DOI":"10.1002\/smll.202000556","article-title":"A multiligand architectural photosensitizer that targets hemagglutinin on envelope of influenza virus for photodynamic inactivation","volume":"16","author":"Jeong","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.drup.2024.101053_bib61","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1002\/jmv.28064","article-title":"Discovery of novel 1,2,4\u2010triazole phenylalanine derivatives targeting an unexplored region within the interprotomer pocket of the HIV capsid protein","volume":"94","author":"Jiang","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.drup.2024.101053_bib62","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/med.21581","article-title":"Molecular design opportunities presented by solvent\u2010exposed regions of target proteins","volume":"39","author":"Jiang","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.drup.2024.101053_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113097","article-title":"Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity","volume":"212","author":"Jia","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4155\/fmc-2018-0397","article-title":"Discovery of novel anti-influenza agents via contemporary medicinal chemistry strategies (2014\u20132018 update)","volume":"11","author":"Jia","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib65","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.drudis.2018.11.012","article-title":"Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors","volume":"24","author":"Jing","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2024.101053_bib66","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1517\/13543776.18.11.1225","article-title":"Advances in two-metal chelation inhibitors of HIV integrase","volume":"18","author":"Johns","year":"2008","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.drup.2024.101053_bib67","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","article-title":"Design, synthesis, and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles","volume":"59","author":"Kang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib68","doi-asserted-by":"crossref","first-page":"15823","DOI":"10.1073\/pnas.1904529116","article-title":"Drugging an undruggable pocket on KRAS","volume":"116","author":"Kessler","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2024.101053_bib69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1232552","article-title":"Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity","volume":"340","author":"Kim","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.drup.2024.101053_bib70","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/s41467-022-29915-z","article-title":"Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease","volume":"13","author":"Kneller","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2024.101053_bib71","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1021\/jm00115a028","article-title":"Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere","volume":"34","author":"Krohn","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib72","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.0502860102","article-title":"Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib","volume":"102","author":"Kwak","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2024.101053_bib73","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1021\/acs.jctc.8b00097","article-title":"Hydration structure and dynamics of inhibitor-bound HIV-1 protease","volume":"14","author":"Leidner","year":"2018","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.drup.2024.101053_bib74","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1021\/acs.jctc.0c01244","article-title":"Deciphering complex mechanisms of resistance and loss of potency through coupled molecular dynamics and machine learning","volume":"17","author":"Leidner","year":"2021","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.drup.2024.101053_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2023.100092","article-title":"Antiviral PROTACs: opportunity borne with challenge","volume":"2","author":"Liang","year":"2023","journal-title":"Cell Insight"},{"key":"10.1016\/j.drup.2024.101053_bib76","doi-asserted-by":"crossref","first-page":"17508","DOI":"10.1074\/jbc.M313020200","article-title":"In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061","volume":"279","author":"Lin","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2020.05.028","article-title":"Developing covalent protein drugs via proximity-enabled reactive therapeutics","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drup.2024.101053_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115501","article-title":"HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues","volume":"257","author":"Lockbaum","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib79","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2217\/fmb.15.74","article-title":"Overcoming drug resistance in HSV, CMV, HBV and HCV infection","volume":"10","author":"L\u00f3pez-Labrador","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.drup.2024.101053_bib80","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","article-title":"Antiviral strategies against influenza virus: towards new therapeutic approaches","volume":"71","author":"Loregian","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.drup.2024.101053_bib81","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0960-894X(01)00412-7","article-title":"Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues","volume":"11","author":"Ludovici","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drup.2024.101053_bib82","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3","article-title":"Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors","volume":"37","author":"Mammen","year":"1998","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.drup.2024.101053_bib83","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2174\/156802609789630910","article-title":"HIV-1 IN inhibitors: 2010 update and perspectives","volume":"9","author":"Marchand","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib84","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1021\/bi800791q","article-title":"Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants","volume":"47","author":"Marinello","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.drup.2024.101053_bib85","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.virusres.2007.12.021","article-title":"HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo","volume":"134","author":"Martinez-Picado","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.drup.2024.101053_bib86","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug design strategies to avoid resistance in direct-acting antivirals and beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drup.2024.101053_bib87","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.drup.2024.101053_bib88","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003495-200161020-00011","article-title":"Oseltamivir: a review of its use in influenza","volume":"61","author":"McClellan","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.drup.2024.101053_bib89","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Men\u00e9ndez-Arias","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.drup.2024.101053_bib90","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(02)02054-0","article-title":"Targeting HIV: antiretroviral therapy and development of drug resistance","volume":"23","author":"Men\u00e9ndez-Arias","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drup.2024.101053_bib91","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"Men\u00e9ndez-Arias","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drup.2024.101053_bib92","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1128\/AAC.05288-11","article-title":"MK-0536 Inhibits HIV-1 integrases resistant to raltegravir","volume":"55","author":"M\u00e9tifiot","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2024.101053_bib93","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1021\/bi100130f","article-title":"Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir","volume":"49","author":"M\u00e9tifiot","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.drup.2024.101053_bib94","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/v2071347","article-title":"Resistance to integrase inhibitors","volume":"2","author":"M\u00e9tifiot","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.drup.2024.101053_bib95","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/QAD.0b013e3283473599","article-title":"Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143","volume":"25","author":"M\u00e9tifiot","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.drup.2024.101053_bib96","doi-asserted-by":"crossref","first-page":"eade8778","DOI":"10.1126\/sciadv.ade8778","article-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors","volume":"9","author":"Moghadasi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2024.101053_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101009","article-title":"Second-site suppressor mutations reveal connection between the drug-binding pocket and nucleotide-binding domain 1 of human P-glycoprotein (ABCB1","volume":"71","author":"Murakami","year":"2023","journal-title":"Drug Resist. Update"},{"key":"10.1016\/j.drup.2024.101053_bib98","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1021\/jm100059d","article-title":"Fragment-based drug discovery applied to hsp90. Discovery of two lead series with high ligand efficiency","volume":"53","author":"Murray","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib99","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/acsptsci.0c00018","article-title":"Investigation of the drug resistance mechanism of M2-S31N channel blockers through biomolecular simulations and viral passage experiments","volume":"3","author":"Musharrafieh","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.drup.2024.101053_bib100","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1574-6976.2011.00290.x","article-title":"Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria","volume":"36","author":"Nikaido","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.drup.2024.101053_bib101","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pbiomolbio.2004.07.005","article-title":"Adaptive inhibitors of the HIV-1 protease","volume":"88","author":"Ohtaka","year":"2005","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib102","doi-asserted-by":"crossref","first-page":"d117","DOI":"10.2741\/957","article-title":"Retroviral mutation rates and reverse transcriptase fidelity","volume":"8","author":"Pathak","year":"2003","journal-title":"Front. Biosci."},{"key":"10.1016\/j.drup.2024.101053_bib103","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drup.2024.101053_bib104","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drup.2024.101053_bib105","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology \u2013 foe or friend?","volume":"56","author":"Peters","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib106","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.chembiol.2019.06.001","article-title":"Analyzing resistance to design selective chemical inhibitors for AAA proteins","volume":"26","author":"Pisa","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib107","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41589-020-0596-8","article-title":"Chemical strategies to overcome resistance against targeted anticancer therapeutics","volume":"16","author":"Pisa","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.drup.2024.101053_bib108","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/ci100128k","article-title":"Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening","volume":"50","author":"Postigo","year":"2010","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.drup.2024.101053_bib109","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","article-title":"Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes","volume":"10","author":"Prabu-Jeyabalan","year":"2002","journal-title":"Structure"},{"key":"10.1016\/j.drup.2024.101053_bib110","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1021\/acs.jctc.7b00601","article-title":"Elucidating the interdependence of drug resistance from combinations of mutations","volume":"13","author":"Ragland","year":"2017","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.drup.2024.101053_bib111","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2024.101053_bib112","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi\u2010target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.drup.2024.101053_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112714","article-title":"Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies","volume":"206","author":"Ren","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib114","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1128\/JVI.00377-11","article-title":"Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3\/4A protease","volume":"85","author":"Romano","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.drup.2024.101053_bib115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/17584310.3.1.63","article-title":"Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1","volume":"3","author":"Rossotti","year":"2009","journal-title":"HIV Ther."},{"key":"10.1016\/j.drup.2024.101053_bib116","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1016\/j.bmcl.2009.09.045","article-title":"Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase","volume":"19","author":"Ruebsam","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drup.2024.101053_bib117","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature05114","article-title":"The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design","volume":"443","author":"Russell","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.drup.2024.101053_bib118","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drup.2024.101053_bib119","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2024.101053_bib120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.drup.2024.101053_bib121","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2024.101053_bib122","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1021\/acs.jmedchem.1c02134","article-title":"The ascension of targeted covalent inhibitors","volume":"65","author":"Singh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib123","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1128\/CMR.00016-09","article-title":"Plasmid-mediated quinolone resistance: a multifaceted threat","volume":"22","author":"Strahilevitz","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.drup.2024.101053_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103491","article-title":"Artificial intelligence as a smart approach to develop antimicrobial drug molecules: a paradigm to combat drug-resistant infections","volume":"28","author":"Talat","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2024.101053_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008536","article-title":"The hallmarks of COVID-19 disease","volume":"16","author":"Tang","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.drup.2024.101053_bib126","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/jac\/dku127","article-title":"A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses","volume":"69","author":"Tarbet","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.drup.2024.101053_bib127","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1073\/pnas.0813029106","article-title":"Docking for fragment inhibitors of AmpC \u03b2-lactamase","volume":"106","author":"Teotico","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2024.101053_bib128","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a Noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib129","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jcb.10068","article-title":"Incorporating target heterogeneity in drug design","volume":"84","author":"Velazquez-Campoy","year":"2001","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.drup.2024.101053_bib130","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/antibiotics11121717","article-title":"A perspective on newly emerging proteolysis-targeting strategies in antimicrobial drug discovery","volume":"11","author":"Venkatesan","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.drup.2024.101053_bib131","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2174\/0929867322666150209151209","article-title":"Target based drug design - a reality in virtual sphere","volume":"22","author":"Verma","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib132","article-title":"Phenotypic drug discovery: recent successes, lessons learned and new directions","author":"Vincent","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drup.2024.101053_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002914","article-title":"H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis","volume":"8","author":"van der Vries","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.drup.2024.101053_bib134","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC","volume":"3","author":"Walter","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drup.2024.101053_bib135","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2217\/epi.15.86","article-title":"Medicinal chemistry insights in the discovery of novel LSD1 inhibitors","volume":"7","author":"Wang","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.drup.2024.101053_bib136","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bip.22623","article-title":"Recent progress in designing inhibitors that target the drug-resistant M2 proton channels from the influenza A viruses: insights for designing inhibitors","volume":"104","author":"Wang","year":"2015","journal-title":"Biopolymers"},{"key":"10.1016\/j.drup.2024.101053_bib137","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1073\/pnas.1216526110","article-title":"Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus","volume":"110","author":"Wang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drup.2024.101053_bib138","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1021\/ja0344967","article-title":"Trypanosoma cruzi trans-sialidase operates through a covalent sialyl\u2212enzyme intermediate: tyrosine is the catalytic nucleophile","volume":"125","author":"Watts","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drup.2024.101053_bib139","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/v13050839","article-title":"HIV protease: historical perspective and current research","volume":"13","author":"Weber","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drup.2024.101053_bib140","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1021\/acs.jmedchem.2c00319","article-title":"Preventing influenza A virus infection by mixed inhibition of neuraminidase and hemagglutinin by divalent inhibitors","volume":"65","author":"Wei","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib141","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1021\/acs.jctc.9b00781","article-title":"Characterizing protein\u2013ligand binding using atomistic simulation and machine learning: application to drug resistance in HIV-1 protease","volume":"16","author":"Whitfield","year":"2020","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.drup.2024.101053_bib142","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2024.101053_bib143","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1021\/jm100060b","article-title":"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design","volume":"53","author":"Woodhead","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib144","doi-asserted-by":"crossref","first-page":"8445","DOI":"10.1021\/jm500892k","article-title":"Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase","volume":"57","author":"Xie","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib145","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","volume":"11","author":"Xiong","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.drup.2024.101053_bib146","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13238-020-00769-9","article-title":"Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase","volume":"11","author":"Xu","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.drup.2024.101053_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2022.100030","article-title":"Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus","volume":"1","author":"Xu","year":"2022","journal-title":"Cell Insight"},{"key":"10.1016\/j.drup.2024.101053_bib148","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cells9010170","article-title":"RK-33 is a broad-spectrum antiviral agent that targets DEAD-Box RNA helicase DDX3X","volume":"9","author":"Yang","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.drup.2024.101053_bib149","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rmv.1879","article-title":"A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action: a new role of NA in the influenza virus life cycle","volume":"26","author":"Yang","year":"2016","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.drup.2024.101053_bib150","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.05438-11","article-title":"Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and Filibuvir","volume":"56","author":"Yi","year":"2012","journal-title":"Antimicrob. Agents Ch"},{"key":"10.1016\/j.drup.2024.101053_bib151","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1021\/ja954069w","article-title":"Irreversible inhibition of the HIV-1 protease: targeting alkylating agents to the catalytic aspartate groups","volume":"118","author":"Yu","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drup.2024.101053_bib152","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1016\/j.chempr.2022.07.012","article-title":"Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants","volume":"8","author":"Yu","year":"2022","journal-title":"Chem"},{"key":"10.1016\/j.drup.2024.101053_bib153","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1021\/acs.jmedchem.8b01065","article-title":"Structure-based optimization of N-substituted oseltamivir derivatives as potent anti-influenza A virus agents with significantly improved potency against oseltamivir-resistant N1-H274Y variant","volume":"61","author":"Zhang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib154","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.drudis.2018.11.021","article-title":"Efficient drug discovery by rational lead hybridization based on crystallographic overlay","volume":"24","author":"Zhang","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drup.2024.101053_bib155","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1021\/acs.jmedchem.7b00596","article-title":"Structure-guided optimization of HIV integrase strand transfer inhibitors","volume":"60","author":"Zhao","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2024.101053_bib156","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drup.2024.101053_bib157","first-page":"285","article-title":"Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality","volume":"3","author":"Zhou","year":"2023","journal-title":"Acta Mater. Med."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764624000116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764624000116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:05:27Z","timestamp":1761282327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764624000116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":157,"alternative-id":["S1368764624000116"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2024.101053","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2024.101053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101053"}}